Search

Your search keyword '"Baz, Rachid"' showing total 687 results
Start Over Author "Baz, Rachid" Search Limiters Full Text
687 results on '"Baz, Rachid"'

1. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

Author

Fortuna, Gliceida Galarza, Banerjee, Rahul, Savid-Frontera, Constanza, Song, Jinming, Morán-Segura, Carlos M., Nguyen, Jonathan V., Lekakis, Lazaros, Fernandez-Pol, Sebastian, Samraj, Annie N., Naresh, Kikkeri N., Vazquez-Martinez, Mariola, Baz, Rachid C., Spiegel, Jay Y., Mikkilineni, Lekha, Gubatan, John M., Sidana, Surbhi, de Menezes Silva Corraes, Andre, Kalariya, Nilesh M., Patel, Krina K., Shim, Kevin G., Fonseca, Rafael, Ferreri, Christopher, Voorhees, Peter M., Richard, Shambavi, Valdes, Cesar Rodriguez, Sireesha Asoori, Wolf, Jeffrey L., Cowan, Andrew J., Sborov, Douglas W., Locke, Frederick L., Lin, Yi, Wang, Yinghong, and Hansen, Doris K.

Published
2024
Full Text
View/download PDF

2. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Author

Lee, Dae Hyun, Kumar, Abhishek, Mohammed, Turab, Peres, Lauren C., Alsina, Melissa, Bachmeier, Christina, Blue, Brandon J., Brayer, Jason, Chandrasekhar, Sanjay, Grajales Cruz, Ariel, De Avila, Gabe, Elmariah, Hany, Faramand, Rawan, Freeman, Ciara, Jain, Michael, Khadka, Sushmita, Khimani, Farhad, Liu, Hien, Nishihori, Taiga, Oswald, Laura B., Castaneda Puglianini, Omar A., Shain, Kenneth H., Smith, Eric, Baz, Rachid C., Locke, Frederick L., Oliveira, Guilherme H., Alomar, Mohammed, and Hansen, Doris K.

Published
2023
Full Text
View/download PDF

3. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.

Author

Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan, Jakubowiak, Andrzej, Dingli, David, Cornell, Robert, Hofmeister, Craig, Siegel, David, Berdeja, Jesus, Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Abonour, Rafat, Parker, Terri, Yee, Andrew, Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja, Mohty, Mohamad, Choquet, Sylvain, Unger, T, Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Dimopoulos, Meletios

Subjects
Aged, Antineoplastic Agents, Appetite, Clinical Trials as Topic, Diarrhea, Fatigue, Female, Humans, Hydrazines, Hyponatremia, Male, Middle Aged, Multiple Myeloma, Nausea, Thrombocytopenia, Triazoles
Abstract

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.

Published
2020

4. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Author

Logue, Jennifer M., Peres, Lauren C., Hashmi, Hamza, Colin-Leitzinger, Christelle M., Shrewsbury, Alexandria M., Hosoya, Hitomi, Gonzalez, Rebecca M., Copponex, Christina, Kottra, Krista H., Hovanky, Vanna, Sahaf, Bita, Patil, Sunita, Lazaryan, Aleksandr, Jain, Michael D., Baluch, Aliyah, Klinkova, Olga V., Bejanyan, Nelli, Faramand, Rawan G., Elmariah, Hany, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Blue, Brandon J., Grajales-Cruz, Ariel F., Castaneda Puglianini, Omar A., Liu, Hien D., Nishihori, Taiga, Freeman, Ciara L., Brayer, Jason B., Shain, Kenneth H., Baz, Rachid C., Locke, Frederick L., Alsina, Melissa, Sidana, Surbhi, and Hansen, Doris K.

Published
2022
Full Text
View/download PDF

5. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Author

Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Jr, Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, and Kaur, Gurbakhash

Published
2024
Full Text
View/download PDF

6. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma

Author

Peres, Lauren C., Colin-Leitzinger, Christelle M., Teng, Mingxiang, Dutil, Julie, Alugubelli, Raghunandan R., DeAvila, Gabriel, Teer, Jamie K., Du, Dongliang, Mo, Qianxing, Siegel, Erin M., Hampton, Oliver A., Alsina, Melissa, Brayer, Jason, Blue, Brandon, Baz, Rachid, Silva, Ariosto S., Nishihori, Taiga, Shain, Kenneth H., and Gillis, Nancy

Published
2022
Full Text
View/download PDF

7. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Author

Richardson, Paul, Hofmeister, Craig, Rosenbaum, Cara, Htut, Myo, Vesole, David, Berdeja, Jesus, Liedtke, Michaela, Chari, Ajai, Smith, Stephen, Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra, Estevam, Jose, Berg, Deborah, and Baz, Rachid

Subjects
ixazomib, multiple myeloma, newly diagnosed, oral, twice-weekly, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boron Compounds, Dexamethasone, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glycine, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Treatment Outcome
Abstract

Weekly ixazomib with lenalidomide-dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice-weekly ixazomib plus Rd in NDMM; 64 patients were enrolled across both phases. Patients received twice-weekly oral ixazomib 3·0 or 3·7 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone. No dose-limiting toxicities were reported in cycle 1; the RP2D was 3·0 mg based on overall tolerability across multiple cycles. In 62 evaluable patients, the confirmed overall response rate was 94% (68% ≥very good partial response; 24% complete response). Median progression-free survival was 24·9 months. Responses (median duration 36·9 months for patients receiving the RP2D) deepened during treatment. Grade 3 drug-related adverse events (AEs) occurred in 64% of patients, including: rash, 13%; peripheral neuropathy, 8%; hyperglycaemia, 8%. There were no grade 4 drug-related AEs. Thirteen patients discontinued due to AEs. Twice-weekly ixazomib-Rd offers substantial activity with promising long-term outcomes in NDMM patients but may be associated with greater toxicity compared with weekly ixazomib-Rd in this setting.

Published
2018

8. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Author

Vogl, Dan T, Dingli, David, Cornell, Robert Frank, Huff, Carol Ann, Jagannath, Sundar, Bhutani, Divaya, Zonder, Jeffrey, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Cole, Craig, Vij, Ravi, Jakubowiak, Andrzej, Abonour, Rafat, Schiller, Gary, Parker, Terri L, Costa, Luciano J, Kaminetzky, David, Hoffman, James E, Yee, Andrew J, Chari, Ajai, Siegel, David, Fonseca, Rafael, Van Wier, Scott, Ahmann, Gregory, Lopez, Ilsel, Kauffman, Michael, Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla D, Choe-Juliak, Cassandra, and Stewart, A Keith

Subjects
Hematology, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Active Transport, Cell Nucleus, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Dose-Response Relationship, Drug, Female, Humans, Hydrazines, Karyopherins, Male, Middle Aged, Multiple Myeloma, Progression-Free Survival, Receptors, Cytoplasmic and Nuclear, Triazoles, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.

Published
2018

9. Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

Author

Shabnaz, Samia, primary, Nguyen, Trang N., additional, Williams, Roy, additional, Rubinstein, Samuel M., additional, Garrett, Timothy J., additional, Tantawy, Marwa, additional, Fradley, Michael G., additional, Alomar, Mohammed E., additional, Shain, Kenneth H., additional, Baz, Rachid C., additional, Lenihan, Daniel, additional, Cornell, Robert F., additional, Lu, Qing, additional, and Gong, Yan, additional

Published
2024
Full Text
View/download PDF

10. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

Author

Akhtar, Othman S., Modi, Karnav, Kim, Jongphil, Skelson, Lawrence, Smith, Eric, Al-Jumayli, Mohammed A., Extermann, Martine, De Avila, Gabriel, Parker, Nathan, Castaneda Puglianini, Omar, Grajales Cruz, Ariel, Baz, Rachid, Blue, Brandon, Shain, Kenneth, Alsina, Melissa, Liu, Hien, Nishihori, Taiga, Jain, Michael D., Locke, Frederick L., Hansen, Doris K., and Freeman, Ciara L.

Published
2024
Full Text
View/download PDF

12. Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts)

Author

Patel, Krina K., primary, Rodríguez-Otero, Paula, additional, Nooka, Ajay K., additional, Callander, Natalie S., additional, Solomon, Scott R., additional, Baz, Rachid, additional, Sborov, Douglas W., additional, Gergis, Usama, additional, Badros, Ashraf Z., additional, Giralt, Sergio A., additional, Pearse, Roger, additional, Abonour, Rafat, additional, Siegel, David S., additional, Larson, Sarah M., additional, Munshi, Nikhil C., additional, Truppel-Hartmann, Anna, additional, Bhatnagar, Rashmi, additional, Wu, Fan, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Mckiver, Mihaela Popa, additional, Jagannath, Sundar, additional, and Ailawadhi, Sikander, additional

Published
2024
Full Text
View/download PDF

13. Evaluation of Outpatient Administration of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Single Center Experience

Author

Waqar, Syed Hamza Bin, primary, Hansen, Doris K, additional, Freeman, Ciara Louise, additional, De Avila, Gabe, additional, Harvey, Kristy, additional, Grajales, Ariel, additional, Blue, Brandon, additional, Liu, Hien, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Shain, Kenneth, additional, Jain, Michael D., additional, Locke, Frederick L., additional, Castaneda, Omar, additional, and Nishihori, Taiga, additional

Published
2024
Full Text
View/download PDF

15. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel

Author

Oswald, Laura B., primary, Gudenkauf, Lisa M., additional, Li, Xiaoyin, additional, De Avila, Gabriel, additional, Peres, Lauren C., additional, Kirtane, Kedar, additional, Gonzalez, Brian D., additional, Hoogland, Aasha I., additional, Nguyen, Oanh, additional, Rodriguez, Yvelise, additional, Baz, Rachid C., additional, Shain, Kenneth H., additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Freeman, Ciara, additional, Castaneda Puglianini, Omar, additional, Nishihori, Taiga, additional, Liu, Hien, additional, Blue, Brandon, additional, Grajales-Cruz, Ariel, additional, Jim, Heather S. L., additional, and Hansen, Doris K., additional

Published
2023
Full Text
View/download PDF

16. P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY

Author

Manier, Salomon, primary, Rodríguez-Otero, Paula, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Bahlis, Nizar J, additional, Munshi, Nikhil, additional, Ailawadhi, Sikander, additional, Arnulf, Bertrand, additional, Nooka, Ajay, additional, Vij, Ravi, additional, Weum Abrahamsen, Ingerid, additional, Broijl, Annemiek, additional, Jagannath, Sundar, additional, Benjamin, Reuben, additional, Gergis, Usama, additional, Sborov, Douglas W., additional, Iida, Shinsuke, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, and Baz, Rachid, additional

Published
2023
Full Text
View/download PDF

18. S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS

Author

Patel, Krina, primary, Rodríguez-Otero, Paula, additional, Manier, Salomon, additional, Baz, Rachid, additional, Raab, Marc S., additional, Cavo, Michele, additional, Callander, Natalie, additional, Costa, Luciano, additional, Moreau, Philippe, additional, Solomon, Scott, additional, Chen, Christine, additional, Raje, Noopur, additional, Scheid, Christof, additional, Delforge, Michel, additional, Larsen, Jeremy, additional, Pabst, Thomas, additional, Suzuki, Kenshi, additional, Truppel-Hartmann, Anna, additional, Yang, Zhihong, additional, Piasecki, Julia, additional, Felten, Jasper, additional, Caia, Andrea, additional, Cook, Mark, additional, Giralt, Sergio, additional, and Mateos, Maria-Victoria, additional

Published
2023
Full Text
View/download PDF

19. PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Mohammed, Turab, primary, Shahzad, Moazzam, additional, Peres, Lauren, additional, Khadka, Sushmita, additional, Colinleitzinger, Christelle, additional, Babu, Abida, additional, Doyle, William, additional, Puglianini, Omar Castaneda, additional, Oswald, Laura, additional, De Avila, Gabe, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon, additional, Ochoa-Bayona, Jose, additional, Smith, Eric, additional, Corallo, Salvatore, additional, Khimani4, Farhad, additional, Faramand, Rawan, additional, Elmariah, Hany, additional, Lazaryan, Aleksandr, additional, Jain, Michael, additional, Liu, Hien, additional, Nishihori, Taiga, additional, Shain, Ken, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick, additional, Freeman, Ciara, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

22. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Author

Garzon, Ramiro, Savona, Michael, Baz, Rachid, Andreeff, Michael, Gabrail, Nashat, Gutierrez, Martin, Savoie, Lynn, Mau-Sorensen, Paul Morten, Wagner-Johnston, Nina, Yee, Karen, Unger, Thaddeus J., Saint-Martin, Jean-Richard, Carlson, Robert, Rashal, Tami, Kashyap, Trinayan, Klebanov, Boris, Shacham, Sharon, Kauffman, Michael, and Stone, Richard

Published
2017
Full Text
View/download PDF

25. Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma

Author

Tantawy, Marwa, primary, Yang, Guang, additional, Algubelli, Raghunandan Reddy, additional, DeAvila, Gabriel, additional, Rubinstein, Samuel M., additional, Cornell, Robert F., additional, Fradley, Michael G., additional, Siegel, Erin M., additional, Hampton, Oliver A., additional, Silva, Ariosto S., additional, Lenihan, Daniel, additional, Shain, Kenneth H., additional, Baz, Rachid C., additional, and Gong, Yan, additional

Published
2023
Full Text
View/download PDF

27. Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/ Refractory Multiple Myeloma (RRMM)

Author

Mohty, Razan, primary, Drekolias, Dimitrios, additional, Peres, Lauren, additional, Freeman, Ciara, additional, Castaneda, Omar, additional, Faramand, Rawan G, additional, Oswald, Laura, additional, Reid, Kayla, additional, De Avila, Gabe, additional, Blue, Brandon Jamaal, additional, Grajales, Ariel, additional, Mohammed, Turab, additional, Ochoa-Bayona, Jose, additional, Shrewsbury, Alexandria M, additional, Doyle, William, additional, Gonzalez, Rebecca, additional, Logue, Jennifer, additional, Elmariah, Hany, additional, Jain, Michael D, additional, Liu, Hien, additional, Brayer, Jason, additional, Shain, Kenneth, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Nishihori, Taiga, additional, Davila, Marco L., additional, Locke, Frederick L., additional, and Hansen, Doris K, additional

Published
2023
Full Text
View/download PDF

28. Anti-BCMA CAR T-Cell Commercial Slot Allocation in Patients with Relapsed/Refractory Multiple Myeloma: Insights from a Single Center Experience

Author

Puglianini, Omar Castaneda, primary, Hansen, Doris K, additional, Grajales-Cruz, Ariel, additional, Blue, Brandon Jamaal, additional, Brayer, Jason, additional, Freeman, Ciara, additional, Shain, Kenneth, additional, Liu, Hien, additional, Ochoa, Leonel, additional, Locke, Frederick L., additional, Baz, Rachid, additional, Alsina, Melissa, additional, and Nishihori, Taiga, additional

Published
2023
Full Text
View/download PDF

29. Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Ionescu, Filip, primary, Freeman, Ciara, additional, Castaneda, Omar, additional, Blue, Brandon Jamaal, additional, Grajales, Ariel, additional, Powell, Cole T., additional, De Avila, Gabe, additional, Peres, Lauren, additional, Oswald, Laura, additional, Ochoa, Leonel, additional, Shrewsbury, Alexandria M, additional, Harvey, Kristy, additional, Quealy, Catherine, additional, Bachmeier, Christina A, additional, Gonzalez, Rebecca, additional, Logue, Jennifer, additional, Faramand, Rawan G, additional, Elmariah, Hany, additional, Jain, Michael D, additional, Liu, Hien, additional, Brayer, Jason, additional, Nishihori, Taiga, additional, Shain, Kenneth, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Altrock, Philipp M, additional, and Hansen, Doris K, additional

Published
2023
Full Text
View/download PDF

30. Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Author

Hansen, Doris K, primary, Peres, Lauren, additional, Freeman, Ciara, additional, Castaneda, Omar, additional, Faramand, Rawan G, additional, Oswald, Laura, additional, Reid, Kayla, additional, De Avila, Gabe, additional, Blue, Brandon Jamaal, additional, Grajales, Ariel, additional, Ochoa, Leonel, additional, Shrewsbury, Alexandria M, additional, Doyle, William, additional, Powell, Cole T., additional, Mohammed, Turab, additional, Gonzalez, Rebecca, additional, Logue, Jennifer, additional, Khimani, Farhad, additional, Elmariah, Hany, additional, Jain, Michael D, additional, Liu, Hien, additional, Brayer, Jason, additional, Nishihori, Taiga, additional, Shain, Kenneth, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Davila, Marco L., additional, and Locke, Frederick L., additional

Published
2023
Full Text
View/download PDF

31. Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Author

Castaneda Puglianini, Omar Alexis, primary, Peres, Lauren C., additional, Hansen, Doris K., additional, Nishihori, Taiga, additional, Grajales-Cruz, Ariel F, additional, Blue, Brandon J., additional, Brayer, Jason, additional, Freeman, Ciara L., additional, Shain, Kenneth H., additional, Liu, Hien D., additional, Ochoa, Jose, additional, Locke, Frederick L., additional, Baz, Rachid C., additional, and Alsina, Melissa, additional

Published
2022
Full Text
View/download PDF

32. Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Author

Renatino-Canevarolo, Rafael, primary, Meads, Mark B., additional, Coelho Siqueira Silva, Maria L., additional, Sudalagunta, Praneeth Reddy, additional, Cubitt, Christopher, additional, De Avila, Gabriel, additional, Alugubelli, Raghunandan Reddy, additional, Kulkarni, Amit, additional, Zhang, Qi, additional, Hampton, Oliver, additional, Baz, Rachid C., additional, Shain, Kenneth H., additional, and Siqueira Silva, Ariosto, additional

Published
2022
Full Text
View/download PDF

33. Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Author

Hashmi, Hamza, primary, Hansen, Doris K., additional, Peres, Lauren C., additional, Castaneda Puglianini, Omar Alexis, additional, Freeman, Ciara L., additional, De Avila, Gabriel, additional, Sidana, Surbhi, additional, Shune, Leyla O., additional, Sborov, Douglas W., additional, Davis, James, additional, Wagner, Charlotte B., additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Simmons, Gary, additional, Ferreri, Christopher J., additional, Kalariya, Nilesh, additional, Sannareddy, Aishwarya, additional, Dima, Danai, additional, Khouri, Jack, additional, McGuirk, Joseph P., additional, Locke, Frederick L., additional, Baz, Rachid C., additional, Patel, Krina, additional, and Alsina, Melissa, additional

Published
2022
Full Text
View/download PDF

34. Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

Author

Parker, Nathan, primary, Modi, Karnav, additional, Villanueva, Ricardo, additional, Skelson, Lawrence, additional, Scotto, Ashley, additional, Booth-Jones, Margaret, additional, De Avila, Gabriel, additional, Jain, Michael D., additional, Mishra, Asmita, additional, Faramand, Rawan, additional, Akhtar, Othman Salim, additional, Brayer, Jason, additional, Castaneda-Puglianini, Omar, additional, Grajales-Cruz, Ariel F., additional, Baz, Rachid C., additional, Blue, Brandon J., additional, Shain, Kenneth H., additional, Alsina, Melissa, additional, Liu, Hien D., additional, Nishihori, Taiga, additional, Locke, Frederick L., additional, Hansen, Doris K., additional, and Freeman, Ciara L., additional

Published
2022
Full Text
View/download PDF

35. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Author

Khouri, Jack, primary, Li, Hong, additional, Hansen, Doris K., additional, Sidana, Surbhi, additional, Shune, Leyla O., additional, DeJarnette, Shaun, additional, Anwer, Faiz, additional, Sborov, Douglas W, additional, Wagner, Charlotte B, additional, Kocoglu, M. Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter M., additional, Valent, Jason, additional, Peres, Lauren C., additional, Hovanky, Vanna, additional, Simmons, Gary, additional, Dima, Danai, additional, Kalariya, Nilesh, additional, Afrough, Aimaz, additional, Kaur, Gurbakhash, additional, Sannareddy, Aishwarya, additional, Ferreri, Christopher J., additional, Davis, James, additional, McGuirk, Joseph P., additional, Locke, Frederick L., additional, Baz, Rachid C., additional, Hamilton, Betty K., additional, Alsina, Melissa, additional, Sauter, Craig S., additional, Hashmi, Hamza, additional, and Patel, Krina, additional

Published
2022
Full Text
View/download PDF

36. Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Author

Baz, Rachid C., primary, Kim, Jongphil, additional, Sam, Christine, additional, Blue, Brandon J., additional, Toska, Sonila, additional, Collier, Aaron, additional, Brayer, Jason, additional, Grajales-Cruz, Ariel F, additional, Alsina, Melissa, additional, Siqueira Silva, Ariosto, additional, and Shain, Kenneth H., additional

Published
2022
Full Text
View/download PDF

37. Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Author

Hansen, Doris K., primary, Peres, Lauren C., additional, Freeman, Ciara L., additional, Castaneda Puglianini, Omar Alexis, additional, Faramand, Rawan, additional, Oswald, Laura B., additional, Reid, Kayla M., additional, De Avila, Gabriel, additional, Blue, Brandon J., additional, Grajales-Cruz, Ariel F., additional, Ochoa, Jose, additional, Shrewsbury, Alexandria, additional, Powell, Cole T., additional, Copponex, Christina, additional, Kottra, Krista H., additional, Gonzalez, Rebecca, additional, Logue, Jennifer M., additional, Khimani, Farhad, additional, Elmariah, Hany, additional, Jain, Michael D., additional, Nishihori, Taiga, additional, Liu, Hien D., additional, Brayer, Jason, additional, Shain, Ken H., additional, Baz, Rachid, additional, Locke, Frederick L., additional, Alsina, Melissa, additional, and Davila, Marco L., additional

Published
2022
Full Text
View/download PDF

38. A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Author

Gonsalves, Wilson I., primary, Neparidze, Natalia, additional, Allred, Jacob B., additional, Kumar, Shaji K, additional, Reid, Joel M., additional, Shapiro, Geoffrey, additional, Costello, Brian A., additional, Piekarz, Richard, additional, Baz, Rachid C., additional, and Devarakonda, Srinivas, additional

Published
2022
Full Text
View/download PDF

39. Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Author

Nishihori, Taiga, primary, Freeman, Ciara L., additional, Hansen, Doris K., additional, Blue, Brandon J., additional, Castaneda Puglianini, Omar Alexis, additional, Kim, Jongphil, additional, Grajales-Cruz, Ariel F., additional, Brayer, Jason, additional, Ochoa, Jose, additional, Liu, Hien D., additional, Shain, Kenneth H., additional, Baz, Rachid C., additional, Locke, Frederick L., additional, and Alsina, Melissa, additional

Published
2022
Full Text
View/download PDF

41. High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Author

Villanueva, Ricardo, primary, Hansen, Doris K., additional, Tonseth, Rolf Petter, additional, Gage, Kenneth L, additional, Wei, Zhouping, additional, De Avila, Gabriel, additional, Baz, Rachid C., additional, Grajales-Cruz, Ariel F, additional, Castaneda-Puglianini, Omar, additional, Blue, Brandon J., additional, Brayer, Jason, additional, Shain, Kenneth H., additional, Alsina, Melissa, additional, Liu, Hien D., additional, Nishihori, Taiga, additional, Menges, Meghan A, additional, Locke, Frederick L., additional, Balagurunathan, Yoganand, additional, and Freeman, Ciara L., additional

Published
2022
Full Text
View/download PDF

42. Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Author

Nishihori, Taiga, primary, Hansen, Doris K., additional, Liu, Hien D., additional, Castaneda Puglianini, Omar Alexis, additional, Freeman, Ciara L., additional, Blue, Brandon J., additional, Brayer, Jason, additional, Kim, Jongphil, additional, Grajales-Cruz, Ariel F, additional, Ochoa, Jose, additional, Baz, Rachid C., additional, Shain, Kenneth H., additional, Locke, Frederick L., additional, and Alsina, Melissa, additional

Published
2022
Full Text
View/download PDF

43. An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Author

Kaufman, Jonathan L., primary, Quach, Hang, additional, Baz, Rachid C., additional, Vangsted, Annette Juul, additional, Ho, Shir-Jing, additional, Harrison, Simon J, additional, Plesner, Torben, additional, Moreau, Philippe, additional, Gibbs, Simon D., additional, Medvedova, Eva, additional, Jalaluddin, Muhammad, additional, Ross, Jeremy A., additional, Lash Fleming, Leanne, additional, Luo, Yan, additional, and Bahlis, Nizar Jacques, additional

Published
2022
Full Text
View/download PDF

44. A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Author

Sudalagunta, Praneeth Reddy, primary, Meads, Mark B., additional, Renatino-Canevarolo, Rafael, additional, Coelho Siqueira Silva, Maria L., additional, Zhao, Xiaohong, additional, Waldron, Rhett, additional, Cubitt, Christopher, additional, Alugubelli, Raghunandan Reddy, additional, De Avila, Gabriel, additional, Hampton, Oliver, additional, Gatenby, Robert, additional, Baz, Rachid C., additional, Shain, Kenneth H., additional, and Siqueira Silva, Ariosto, additional

Published
2022
Full Text
View/download PDF

46. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Author

Richardson, Paul G., Siegel, David S., Vij, Ravi, Hofmeister, Craig C., Baz, Rachid, Jagannath, Sundar, Chen, Christine, Lonial, Sagar, Jakubowiak, Andrzej, Bahlis, Nizar, Song, Kevin, Belch, Andrew, Raje, Noopur, Shustik, Chaim, Lentzsch, Suzanne, Lacy, Martha, Mikhael, Joseph, Matous, Jeffrey, Vesole, David, Chen, Min, Zaki, Mohamed H., Jacques, Christian, Yu, Zhinuan, and Anderson, Kenneth C.

Published
2014
Full Text
View/download PDF

50. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Author

Richardson, Paul G., Siegel, David, Baz, Rachid, Kelley, Susan L., Munshi, Nikhil C., Laubach, Jacob, Sullivan, Daniel, Alsina, Melissa, Schlossman, Robert, Ghobrial, Irene M., Doss, Deborah, Loughney, Nora, McBride, Laura, Bilotti, Elizabeth, Anand, Palka, Nardelli, Lisa, Wear, Sandra, Larkins, Gail, Chen, Min, Zaki, Mohamad H., Jacques, Christian, and Anderson, Kenneth C.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results